Our Pipeline

Our Pipeline

Ganaxolone, through its validated GABAA mechanism, has opportunities in orphan indications and in chronic and acute care settings.

Clinical Trial Information

Ganaxolone is currently being developed in three different dose forms (IV, capsule, and liquid) intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings.

Marinus is currently conducting studies in CDKL5 deficiency disorder, postpartum depression, and refractory status epilepticus.

Learn More

healthy mom happy children


patient resources

Explore Patient Resources

Find helpful information and patient networks, as well as clinical trial opportunities.

View Patient Resources



Find publications referencing ganaxolone and its affect on seizures and neuropsychiatric disorders.

Read More